Leveraging Real World Genomic Data to Advance Prostate Cancer Precision Oncology

Leveraging Real World Genomic Data to Advance Prostate Cancer Precision Oncology

Bibliographic Details
Main Authors:	Beltran, H. (Author), Morgans, A.K (Author)
Format:	Article
Language:	English
Published:	Elsevier B.V. 2022
Subjects:	accuracy androgen deprivation therapy androgen receptor antagonist artificial intelligence biological marker cancer center cancer prognosis clinical decision making clinical trial (topic) cross resistance data base docetaxel Editorial genomics human machine learning male medical record metastatic castration resistant prostate cancer metastatic castration sensitive prostate cancer oncology overall survival personalized medicine prostate cancer prostate specific antigen retinoblastoma protein systemic therapy taxane derivative tumor-related gene
Online Access:	View Fulltext in Publisher

Similar Items

Role of chemotherapy in prostate cancer
by: Rita Nader, et al.
Published: (2018-01-01)

Taxane chemotherapy for hormone-naïve prostate cancer with its expanding role as breakthrough strategy
by: Masaki eShiota, et al.
Published: (2016-01-01)

Prediction for survival following docetaxel-based chemotherapy in Taiwanese men with castration-resistant metastatic prostate cancer
by: Kai-Fu Yang, et al.
Published: (2015-12-01)

Novel Strategies for Treating Castration-Resistant Prostate Cancer
by: David Ka-Wai Leung, et al.
Published: (2021-03-01)

Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer
by: Carlo Cattrini, et al.
Published: (2021-09-01)

Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter “real life” study
by: Luca Cindolo, et al.
Published: (2017-11-01)

Androgen receptor and prostate cancer
by: Karen E. Livermore, et al.
Published: (2016-06-01)

Androgen Receptor-Dependent Mechanisms Mediating Drug Resistance in Prostate Cancer
by: Marzieh Ehsani, et al.
Published: (2021-03-01)

A Review of the Pathophysiological Mechanisms Underlying Castration-resistant Prostate Cancer
by: Crowley F, et al.
Published: (2021-06-01)

TAXANES IN THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER
by: T. N. Skvortsova, et al.
Published: (2017-01-01)

Higher Serum Testosterone Levels Associated with Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer
by: Shinichi Sakamoto, et al.
Published: (2019-04-01)

Current opportunities of therapy for patients with non-metastatic castration-resistant prostate cancer
by: B. Ya. Alekseev, et al.
Published: (2020-11-01)

Successive xanthogranulomatous prostatitis after complete remission of metastatic prostate adenocarcinoma: An extremely rare case report with review of literatures
by: Che-Hsueh Yang, et al.
Published: (2020-07-01)

Chemotherapy in the treatment of metastatic prostate cancer: the present state of the problem
by: B. Ya. Alekseev
Published: (2015-09-01)

Androgen receptor targeted therapies in metastatic castration-resistant prostate cancer – The urologists' perspective
by: Jo-Lynn Tan, et al.
Published: (2017-12-01)

Effectiveness of Deferred Combined Androgen Blockade Therapy Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel
by: Jian-Ri Li, et al.
Published: (2017-11-01)

Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post Hoc Analysis of the PROSELICA Study
by: Nicolas Delanoy, et al.
Published: (2021-03-01)

Data of relative mRNA and protein abundances of androgen receptor splice variants in castration-resistant prostate cancer
by: Tianfang Ma, et al.
Published: (2021-02-01)

Undesirable Status of Prostate Cancer Cells after Intensive Inhibition of AR Signaling: Post-AR Era of CRPC Treatment
by: Tomoyuki Makino, et al.
Published: (2021-04-01)

Titration of Androgen Signaling: How Basic Studies Have Informed Clinical Trials Using High-Dose Testosterone Therapy in Castrate-Resistant Prostate Cancer
by: Steven K. Nordeen, et al.
Published: (2021-08-01)

Editorial: Response and Resistance in Castration-Resistant Prostate Cancer
by: Renée de Leeuw, et al.
Published: (2020-10-01)

CLINICAL ASSESSMENT OF TAXANES IN THE FIRST-LINE CYTOTOXIC THERAPY OF CASTRATION-RESISTANT PROSTATE CANCER
by: A. A. GRITSKEVICH, et al.
Published: (2016-12-01)

EVALUATION OF EFFECT OF PROLONGED ACTION SOMATOSTATIN ANALOGUE – OCREOTIDE-DEPO – ON THE FOLLOWING HORMONAL AND CYTOTOXIC THERAPY IN PATIENTS WITH METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (М-CRPC)
by: S. V. Mishugin, et al.
Published: (2017-11-01)

An interim analysis of non-interventional study of the epidemiology and natural history of non-metastatic castration-resistant prostate cancer in Russia
by: B. Ya. Alekseev, et al.
Published: (2020-11-01)

Abiraterone acetate for early stage metastatic prostate cancer: patient selection and special considerations
by: Castellan P, et al.
Published: (2018-12-01)

Recent Scientific Developments in Metastatic Prostate Cancer
by: Isabel Heidegger
Published: (2020-11-01)

Darolutamide For Castration-Resistant Prostate Cancer
by: Bastos DA, et al.
Published: (2019-10-01)

Serum testosterone level predicts the effective time of androgen deprivation therapy in metastatic prostate cancer patients
by: Yue Wang, et al.
Published: (2017-01-01)

POSSIBILITIES OF RADIUM-223 APPLICATION IN THERAPY OF PROSTATE GLAND CANCER
by: A. A. GRITSKEVICH, et al.
Published: (2017-06-01)

Characterization of Novel Progression Factors in Castration-Resistant Prostate Cancer Based on Global Comparative Proteome Analysis
by: Ann-Yae Na, et al.
Published: (2021-07-01)

Clinical relevance of androgen receptor alterations in prostate cancer
by: Emma Jernberg, et al.
Published: (2017-10-01)

Prognostic Impact of Genetic Polymorphism in Mineralocorticoid Receptor and Comorbidity With Hypertension in Androgen-Deprivation Therapy
by: Masaki Shiota, et al.
Published: (2018-12-01)

Cabazitaxel in the treatment of castration-resistant cancer: hitting the balance of efficacy and safety
by: M. I. Volkova, et al.
Published: (2019-06-01)

Efficacy and Prognostic Factors of Docetaxel Rechallenge on Metastatic Castration-resistant Prostate Cancer Patients
by: DUAN Liqun, et al.
Published: (2019-09-01)

Darolutamide: An Evidenced-Based Review of Its Efficacy and Safety in the Treatment of Prostate Cancer
by: Crawford ED, et al.
Published: (2020-07-01)

Real-world experience with abiraterone in metastatic castration-resistant prostate cancer
by: Yasar Ahmed, et al.
Published: (2017-01-01)

Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer
by: Edoardo Francini, et al.
Published: (2021-08-01)

Outcomes of patients older than 75 years with non-metastatic prostate cancer
by: Yoshiyasu Amiya, et al.
Published: (2017-04-01)

The Role of Docetaxel in Non-Castrate Resistant Metastatic Prostate Cancer: An Evidence-based Case Report
by: Fakhri Rahman, et al.
Published: (2017-04-01)

Ureteral metastasis from locally invasive, castrate-resistant prostate cancer: a case report
by: Zachary C. Janatpour, et al.
Published: (2021-11-01)